Abstract: A monitoring system based on a digital converter station includes a first monitoring terminal deployed at a first-level monitoring side, a second monitoring terminal deployed at a second-level monitoring side, and a third monitoring terminal deployed at a third-level monitoring side; the monitoring terminal at each level includes a communication module, a human-machine interaction module, a device status monitoring module, a device alarm management module, a video fusion processing module, and a data transmission adjustment and control module.

Abstract: Method and an IoT system for gas gate station monitoring are provided. The method includes obtaining operation data of a gas gate station; obtaining a downstream user feature corresponding to the gas gate station and historical warning data corresponding to the gas gate station; determining, based on the downstream user feature and the historical warning data and in combination with the operation data, the associated node in a preset time period, the associated node including at least one of a gate station internal node and an external pipeline network node; obtaining monitoring data of the associated nodes, the monitoring data at least including node monitoring data of the gate station internal node and node monitoring data of the external pipeline network node; and issuing a warning notification in response to the monitoring data not satisfying a preset condition.

Abstract: The present invention relates to methods for treating patients with cancer, including patients with hematological malignancy, wherein the method comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are as defined herein.

Abstract: The invention relates to the technical field of radar detection, in particular to a device for real-time detection of spectrum from airborne hyperspectral imaging LiDAR and method thereof. The device comprises a laser and a reference module; the reference module comprises a first reflecting mirror and a second reflecting mirror with a given transmittance; the first reflecting mirror and the second reflecting mirror are arranged with a focusing mirror and an optical fiber in sequence therebetween. The laser emits a laser light to the first reflecting mirror with a given transmittance, and the beam of the laser light transmitted through the first reflecting mirror after passing the focusing mirror is used as the reference beam after passing the optical fiber. The invention enables detection of the spectral line of each pulse and improves the precision of reflection spectrum of the ground object measured by the system.

Abstract: A method for monitoring mechanochemical activation of metal powders in dynamic electrochemical environment and a device thereof are provided. The method includes constructing a dynamic testing environment in an electrochemical cell, using a three-electrode system, and collecting data from an external electrochemical workstation. The three-electrode system is composed of the working metal plate, the reference electrode, and the platinum electrode. The dynamic testing environment includes small load impacts and changes in pH and composition of the solution. Under the premise of simulating the production environment of the mechanical plating and the water-based metal coating material, the monitoring method described in the present disclosure cooperates with an electrochemical workstation for OCPT testing to achieve the monitoring of mechanochemical activation of metal powders in dynamic electrochemical environment.

Abstract: Techniques are disclosed for implementing cross-zone communication for computing zones executing different coding protocols. A server computer system may receive, via a proxy layer of a first instance of an application executing within a first computing zone according to a first set of coding protocols, a request for a service executed via a second instance of the application in a second computing zone according to a second, different set of coding protocols. The system may alter, via a remote layer of the first instance, a set of data specified in the request to comply with the second, set of protocols. The system may transmit, via the remote layer of the first instance to a remote layer of the second instance, the altered set of data. The system may advantageously provide a simplified development interface allowing for both development and testing within a local environment without deployment of multiple different services.

Abstract: The embodiments of the present disclosure provide a method and smart gas Internet of Things (IoT) system for determining a gas abnormity for a safe gas use. The method is implemented by a smart gas IoT system including a smart gas user platform, a smart gas service platform, a smart gas safety management platform, a smart gas indoor device sensing network platform, and a smart gas indoor device object platform. The method is performed by the smart gas safety management platform, including: receiving request information of a target user, the request information including a request of the target user for analyzing a gas abnormity cause; extracting user data based on the request information, and extracting gas data based on the user data; and determining, based on the user data and the gas data, analysis information of the gas abnormity cause.

Abstract: A method for operating a graph database, including receiving, by a computer system, a query to a particular graph database, the query identifying a plurality of vertices of the particular graph database. The method further includes performing, by the computer system, hash operations on two or more of the plurality of vertices to generate respective hash values and dividing, using the respective hash values, the query into a plurality of sub-queries, each corresponding to a subset of the plurality of vertices. The method also includes sending, by the computer system, ones of the plurality of sub-queries to a plurality of database repositories for the particular graph database.

Abstract: Embodiments of the present disclosure relate to automated validation of medical data. Some embodiments of the present disclosure provide a method for medical data validation. The method comprises obtaining target medical data generated in a medical test and obtaining a machine learning model for validating medical data. The machine learning model represents an association between the medical data and validation results, the validation results indicating information about predetermined actions to be performed on the medical data. The method further comprises determining a target validation result for the target medical data by applying the target medical data to the machine learning model, the target validation result indicating information about a target action selected from the predetermined actions to be performed on the target medical data. Through the solution, it is possible to achieve automated medical data validation with high accuracy and efficiency as well as reduced manual efforts.

Abstract: Disclosed herein are anti-mesothelin antibodies and antigen-binding fragments, chimeric antigen receptors (“CARs”) having these anti-mesothelin antibodies and antigen-binding fragments (“mesothelin CARs”) and genetically modified immune effector cells having such mesothelin CARs. Polynucleotides encoding the anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. Compositions comprising anti-mesothelin antibodies and antigen-binding fragments and mesothelin CARs are also provided herein. The present disclosure also relates to uses of the anti-mesothelin antibodies and antigen-binding fragments and genetically modified immune effector cells having such mesothelin CARs in cancer treatment.

Abstract: The present disclosure provides modified immune cell (e.g., modified T cell) comprising an exogenous T cell receptor (TCR) having specificity for NY-ESO-1. The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising an exogenous TCR and a switch receptor. Gene edited modified cells are also provided, such that the expression of one or more of an endogenous T-cell receptor gene (e.g., TRAC, TRBC) or an endogenous immune checkpoint gene (e.g. PD-1 or TIM-3) is downregulated.

Abstract: A stroke decision device 30 includes an acquisition section 31 configured to acquire state information including a position, a velocity, and a rotational velocity of an incoming ball, and a stroke decision section 32 configured to decide a stroke condition including a position, a velocity, and an orientation of a striking implement at a time point when hitting back the ball toward a target arrival position, based on the state information for the ball and the target arrival position when hitting back the ball with the striking implement.

Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.

Abstract: The present disclosure relates to a molecular marker of the IGF2BP1 gene related to a chicken body size trait and the use thereof, and a genetic improvement method. In the present disclosure, it is found by means of gene association analysis that a deletion mutation in a promoter region of the IGF2BP1 gene of chicken is significantly associated with the chicken body size trait.

Abstract: The present disclosure provides a series battery pack capacity on-line monitoring and charging/discharging dual-state equalization circuit and method. The series battery pack capacity on-line monitoring and charging/discharging dual-state equalization circuit includes a storage battery pack, a gating switch array, a power dissipation loop, a polarity matching switch array, an isolated DC/DC converter, a bipolar differential battery voltage measurement circuit, a micro controller unit, a charging/discharging current detection loop, and a switch circuit unit. According to the present disclosure, each series battery of the storage battery pack can be separately charged and discharged by controlling the gating switch array, the storage battery pack capacity can be detected on line, bypass discharge and parallel supplement can be carried out on the series batteries with high or low relative state of charge in two states of charging and discharging, and the power of each series battery can be efficiently equalized.

Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a T cell, genetically modified to express a chimeric antigen receptor (CAR), a bispecific antibody, or a combination thereof to a subject. The CAR and bispecific antibody of the invention can comprise a human antibody, a humanized antibody, or antigen-binding fragments thereof.

Abstract: The present application relates to an antigen-binding protein and use thereof, wherein the antigen-binding protein comprises a VH and a VL, wherein the VH comprises an HCDR1, an HCDR2 and an HCDR3, wherein the HCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 10, the HCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 12, the HCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 14; and the VL comprises an LCDR1, an LCDR2 and an LCDR3, wherein the LCDR1 comprises an amino acid sequence as set forth in SEQ ID NO: 2, the LCDR2 comprises an amino acid sequence as set forth in SEQ ID NO: 4, and the LCDR3 comprises an amino acid sequence as set forth in SEQ ID NO: 6. The present application also relates to a pharmaceutical composition comprising the antigen-binding protein and use thereof for the treatment of a cancer.

Abstract: The present disclosure provides modified immune cell (e.g., modified T cell) comprising an exogenous T cell receptor (TCR) having specificity for NY-ESO-1. The present disclosure provides modified immune cells or precursors thereof (e.g., modified T cells) comprising an exogenous TCR and a switch receptor. Gene edited modified cells are also provided, such that the expression of one or more of an endogenous T-cell receptor gene (e.g., TRAC, TRBC) or an endogenous immune checkpoint gene (e.g., PD-1 or TIM-3) is downregulated.